The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer.

被引：0
|
作者：
Zhao, Jie [1 ]
Dong, Yiting [1 ]
Bai, Hua [1 ]
Duan, Jianchun [1 ]
Wang, Guoqiang [2 ]
Xu, Jiachen [1 ]
Wang, Zhijie [1 ]
Wang, Jie [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China
[2] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1614
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Jung, Chi Young
    Antonia, Scott J.
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (01) : 29 - 41
  • [2] The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age
    Wu, Yongfeng
    Xu, Jinming
    Xu, Jiawei
    Wang, Yiqing
    Wang, Luming
    Lv, Wang
    Hu, Jian
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [3] The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
    Yongfeng Wu
    Jinming Xu
    Jiawei Xu
    Yiqing Wang
    Luming Wang
    Wang Lv
    Jian Hu
    Biomarker Research, 8
  • [4] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [5] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [6] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Xi Chen
    Liangjie Fang
    Yanping Zhu
    Zhang Bao
    Qing Wang
    Rong Liu
    Wenjia Sun
    Haiwei Du
    Jing Lin
    Bing Yu
    Songan Chen
    Jianya Zhou
    Jianying Zhou
    Cancer Immunology, Immunotherapy, 2021, 70 : 3513 - 3524
  • [7] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Chen, Xi
    Fang, Liangjie
    Zhu, Yanping
    Bao, Zhang
    Wang, Qing
    Liu, Rong
    Sun, Wenjia
    Du, Haiwei
    Lin, Jing
    Yu, Bing
    Chen, Songan
    Zhou, Jianya
    Zhou, Jianying
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) : 3513 - 3524
  • [8] Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Lea
    Heeke, Simon
    Humbert, Olivier
    Macocco, Adam
    Long-Mira, Elodie
    Lassalle, Sandra
    Lespinet-Fabre, Virginie
    Lalvee, Salome
    Bordone, Olivier
    Cohen, Charlotte
    Leroy, Sylvie
    Hofman, Veronique
    Hofman, Paul
    Ilie, Marius
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S71 - S80
  • [9] The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
12345